Fennec Q2 PEDMARK revenue $3.3M, up 98% QoQ; appoints Adrian Haigh as COO

FENNEC PHARMACEUTICALS INC.

2023-Q2 EPS reported -$0.43 revenue$5,002,000

Net product sales of PEDMARK $3.3M, a 98% sequential increase from Q1 2023.
Net loss of $5.4M ($0.21/share) vs $5.1M ($0.19/share) in Q2 2022.
Cash and equivalents $15.0M; management says sufficient for at least 12 months.
Appointed Adrian Haigh as COO; he steps down from the board of directors.
Management to present at Wedbush PacGrow Healthcare Conference on August 8-9, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FENNEC PHARMACEUTICALS INC. reported second quarter ended June 30, 2023 results: revenue $3.3 million, net income $5.4 million ($0.21 per share), EPS ($0.21 per share).

Period: second quarter ended June 30, 2023
Revenue: $3.3 million
Net income: $5.4 million ($0.21 per share)
EPS: ($0.21 per share)
Result: reported results

Exact text from the filing

2023 and provided a business update. “During the second quarter, we continued to make strong progress with the U.S. commercial launch of PEDMARK ® , delivering net revenue of $3.3 million, which is a 98% increase in net revenue over the first quarter of 2023. These results reflect strong growth in patient starts and new account orders,” said Rosty Raykov, chief

View on SEC.gov

Browse all earnings releases →

FENNEC PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-087630

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.